Simultaneous inhibition of ID1 and ID3 mitigates fibroblast activation via cell cycle and MEK/ERK pathways in pulmonary fibrosis
Samar A Antar, Eric Mensah, Jacob Dahlka, Mark C Renton, Ahmed A Raslan, Michael Aziz, Aymen Halouani, Seun Imani, Aanandi Parashar, Scott R Johnstone, Robert Benezra, Diego Fraidenraich, Giovanni Ligresti, Yassine Sassi · 2026
Read Simultaneous inhibition of ID1 and ID3 mitigates fibroblast activation via cell cycle and MEK/ERK pathways in pulmonary fibrosis by Samar A Antar, Eric Mensah, Jacob Dahlka, Mark C Renton, Ahmed A Raslan, Michael Aziz, Aymen Halouani, Seun Imani, Aanandi Parashar, Scott R Johnstone, Robert Benezra, Diego Fraidenraich, Giovanni Ligresti, Yassine Sassi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13142238.txt.
Description
Samar Antar and a large team identify two proteins that drive scarring in a fatal lung disease, in a research paper from 2026. The disease, idiopathic pulmonary fibrosis, slowly stiffens the lungs. A growth signal switches lung fibroblasts into scar-forming mode, and two DNA-binding proteins sit downstream of that signal.
Both proteins were raised in scarred lung tissue from mice and patients. Blocking them together slowed fibroblast growth, movement, and scar-forming change in the lab. Mice lacking both genes had less scarring and better lung function after injury. A drug that blocks the pair also eased fibrosis in mice. The authors propose them as a treatment target.
Catalog record
| CREATOR | Samar A Antar, Eric Mensah, Jacob Dahlka, Mark C Renton, Ahmed A Raslan, Michael Aziz, Aymen Halouani, Seun Imani, Aanandi Parashar, Scott R Johnstone, Robert Benezra, Diego Fraidenraich, Giovanni Ligresti, Yassine Sassi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |